Treatment outcomes and late toxicities in patients with embryonal central nervous system tumors

Radiation Oncology

Table 1 Clinical and treatment-related information for patients with average-risk embryonal central nervous system tumors

	Patient no.	Sex	Age at diagnosis (years)	Age at the start of RT (years)	CSI dose (Gy)	Boost dose (Gy)	Follow-up time from diagnosis (months)	Disease progression after RT	Age at the last assessment (years)	Status	Initial height (SDS)	Latest height (SDS)	Hypothyroidism	Ototoxicity (Brock grade)	Initial FSIQ	Latest FSIQ
Medulloblastoma
	1	F	3.5	3.3	18	54	39	–	6.8	NED	-1.1	-2.2	Subclinical	NE	NE	71
	2	M	4.9	5.0	23	54	33	LR	7.7	DOD	-1.5	-3.5	NE	4	NE	NE
	3	M	6.7	6.9	26	54.3	76	–	13.0	NED	+1.3	+0.4	–	1	98	59
	4	M	7.1	7.3	23	54	94	–	14.9	NED	-1.8	-2.5	Subclinical	0	112	110
	5	M	7.2	7.3	23	54	98	LF	15.3	AWD	-0.5	-2.6	Subclinical	2	135	128
	6	M	9.4	9.6	23	54	34	–	12.3	NED	+1.0	+0.1	NE	2	NE	NE
	7	M	10.2	10.4	23	54	48	–	14.2	NED	+1.2	-0.2	–	1	81	82
	8	F	12.8	12.9	23	55.8	94	–	20.6	NED	+1.0	+0.2	NE	2	NE	NE
	9	F	16.0	16.3	23	54	79	–	22.6	NED	+1.0	+0.9	Subclinical	NE	NE	NE

Abbreviations: AWD alive with disease, CSI craniospinal irradiation, DOD death of disease, FSIQ full-scale intelligence quotient; LF local failure; LR leptomeningeal recurrence; NE not evaluated, NED no evidence of disease, RT radiation therapy, SDS standard deviation score.

ISSN: 1748-717X